Document is current
Any future updates will be listed below
-
Authors
van der Hiel, Bernies https://orcid.org/0000-0001-8158-405X
de Wit - van der Veen, Berlinda J.
van den Eertwegh, Alfons J. M.
Vogel, Wouter V.
Stokkel, Marcel P. M.
Lopez-Yurda, Marta
Boellaard, Ronald
Kapiteijn, Ellen W.
Hospers, Geke A. P.
Aarts, Maureen J. B.
de Vos, Filip Y. F. L.
Boers-Sonderen, Marye J.
van der Veldt, Astrid A. M.
de Groot, Jan Willem B.
Haanen, John B. A. G.
-
Funding
Funding for this research was provided by:
F. Hoffmann-La Roche (F. Hoffmann-La Roche)
- License Information
-
More Information
Article History
Received: 1 February 2025
Accepted: 14 May 2025
First Online: 28 May 2025
Declarations
:
: The Medical Ethical Committee of the Netherlands Cancer Institute approved the study for all participating centers. Informed consent was obtained from all participants before entering the study.
: The authors affirm that human research participants provided informed consent for publication of the manuscript.
: AvdE: Study grant: Roche, Idera, Travel expenses: Ipsen Advisory Board: Bristol-Myers Squibb, MSD Oncology, Ipsen, Janssen Cilag BV, Pierre Fabre EK: consultancy/advisory relationships with Bristol Myers Squibb, Novartis, Merck, Pierre Fabre, Lilly and Bayer, all paid to institute, received research grants not related to this paper from Bristol Myers Squibb, Delcath, Novartis and Pierre Fabre. GH: consultancy/advisory relationships with Amgen, Bristol-Myers Squibb, Roche, MSD, Pfizer, Novartis, Sanofi, Pierre Fabre, all paid to institute, received research grants from Bristol-Myers Squibb, Seerave, all paid to institute. MA: advisory board / consultancy honoraria from Amgen, Bristol Myers Squibb, Novartis, MSD-Merck, Merck-Pfizer, Pierre Fabre, Sanofi, Astellas, Bayer. Research grants Merck-Pfizer, all paid to institute and not related to current work. FdV: received research grant from Foundation STOPBraintumors.org, BMS, Novartis, Servier, CureVac, EORTC, all paid to institute. AvdV: consultancy roles (all paid to the institute) for BMS, MSD, Roche, Sanofi, Novartis, Pierre Fabre, Merck, Ipsen, Eisai, Pfizer, all paid to the institute. JH: advisory roles for BMS, CureVac, GSK, Ipsen, Iovance Biotherapeutics, Imcyse, Merck Serono, Molecular Partners, MSD, Novartis, Pfizer, Roche, Sanofi, Third Rock Ventures, member of SAB of Achilles Tx, BioNTech, Gadeta, Immunocore, Instil Bio, PokeAcell, Scenic, T-Knife and Neogene Tx, all paid to institute except Neogene Tx and Scenic, received grant support from Amgen, Asher Bio, BioNTech, BMS, MSD, Novartis, and Sastra Cell Therapy, all paid to institute. The other authors declare no conflict of interest.
